# Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg

> **NCT00350207** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 388 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Tiotropium bromide
- **DRUG:** Placebo
- **DRUG:** Salmeterol xinafoate

## Key facts

- **NCT ID:** NCT00350207
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-09
- **Final completion:** —
- **Target enrollment:** 388 (ACTUAL)
- **Last updated:** 2013-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00350207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00350207, "Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00350207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*